|
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4303-4307.
Prepublished online as a Blood First Edition Paper on August 25, 2005; DOI 10.1182/blood-2005-03-1010.
 Previous Article | Next Article 
Submitted March 14, 2005
Accepted August 11, 2005
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia (ALL)
Stefan Faderl, Kim-Anh Do, Marcy M Johnson, Michael Keating, Susan O'Brien, I Jilani, Alessandra Ferrajoli, Farhad Ravandi-Kashani, C Aguilar, A Dey, Deborah A Thomas, Francis J Giles, Hagop M Kantarjian, and Maher Albitar*
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
* Corresponding author; email: maher.x.albitar{at}questdiagnostics.com.
Angiogenesis plays an important role in solid tumors and hematologic malignancies. The prognostic significance of angiogenic factors in adult acute lymphoblastic leukemia (ALL) remains ambiguous. We therefore analyzed the impact of angiogenic factor levels on overall survival of newly diagnosed adult ALL patients. Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukins (IL)-1 receptor alpha (IL-1R ), IL-6, IL-8, VEGF receptors VEGFR1 and VEGFR2, and thromobpoietin (TPO) were measured in plasma samples of 95 patients by enzyme-linked immunosorbent assay (ELISA). In a univariate Cox proportional hazards model, higher levels of IL-1R, IL-8, VEGFR1 and VEGFR2 predicted for poor survival. In contrast, higher levels of VEGF predicted for longer survival and higher levels of bFGF suggested a similar trend (p=.09). The multivariate model simultaneously included VEGF (relative risk [RR] of death 8.01, p=.001 for levels  19.5 pg/mL), IL-1R (RR 5.12, p=.007 for levels > 373 pg/mL), and VEGFR2 (RR 4.01, p=.04 for levels > 8222 pg/mL) as independent factors for survival. Of interest is the association of high levels of VEGF with good prognosis and higher levels of VEGF receptors with poor outcome. These data reflect the complexity in which angiogenic factors may affect the clinical behavior in patients with ALL and this complexity should be considered in any therapeutic strategy incorporating anti-angiogenic agents.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. T. Scupoli, M. Donadelli, F. Cioffi, M. Rossi, O. Perbellini, G. Malpeli, S. Corbioli, F. Vinante, M. Krampera, M. Palmieri, et al.
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-{kappa}B and JNK/AP-1 pathways
Haematologica,
April 1, 2008;
93(4):
524 - 532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M.L. Ebos, C. R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A. J. Mutsaers, D. J. Dumont, and R. S. Kerbel
Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth
Cancer Res.,
January 15, 2008;
68(2):
521 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis
Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962
Clin. Cancer Res.,
December 1, 2006;
12(23):
6978 - 6984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
